Imre study
This article was originally published in The Gray Sheet
Executive Summary
Published in the March issue of Cancer, the journal of the American Cancer Society, finds that 25 of 55 patients with chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome responded to treatment with the Imre Prosorba immunoadsorption column. Of the patients who responded, 61% had an "estimated one-year survival rate." Only 22% of patients who did not respond to the Prosorba therapy demonstrated a one-year survival rate. In the study, Harry Snyder, PhD, Imre Corporation, et al. find "protein A immunoadsorption...an effective and safe treatment for cancer chemotherapy-associated TTP/HUS".
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.